ArticleJournal of medicinal chemistry2024

A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19.

Charlotte M N Allerton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.